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Abstract 
Ulcerative colitis (UC) is a form of inflam-
matory bowel disease (IBD) characterized by
damage of large bowel mucosa and frequent
extra-intestinal  autoimmune  comorbidities.
The role played in IBD pathogenesis by molec-
ular chaperones known to interact with compo-
nents  of  the  immune  system  involved  in
inflammation  is  unclear.  We  previously
demonstrated  that  mucosal  Hsp60  decreases
in UC patients treated with conventional ther-
apies  (mesalazine,  probiotics),  suggesting
that this chaperonin could be a reliable bio-
marker  useful  for  monitoring  response  to
treatment,  and  that  it  might  play  a  role  in
pathogenesis. In the present work we investi-
gated three other heat shock protein/molecular
chaperones:  Hsp10,  Hsp70,  and  Hsp90.  We
found  that  the  levels  of  these  proteins  are
increased in UC patients at the time of diagno-
sis and decrease after therapy,  supporting the
notion that these proteins deserve attention in
the study of the mechanisms that promote the
development and maintenance of IBD, and as
biomarkers  of  this  disease  (e.g.,  to  monitor
response  to  treatment  at  the  histological
level).
Introduction
Heat shock proteins (Hsps) are a family of
molecules highly conserved throughout evolu-
tion  that  are  typically  involved  in  folding,
refolding,  translocation  and  degradation  of
intracellular proteins under normal and stress
conditions.1,2 In addition, Hsps have received
attention from immunologists because, when
present in the extracellular environment, they
can trigger an inflammatory response.3 Hsps
can  stimulate  innate  and  adaptive  immune
responses  and  can  also,  by  virtue  of  the
sequence  similarity  between  bacterial  and
human orthologs, become primary targets of
autoimmunity due to a phenomenon known as
molecular  mimicry.4 Thus,  Hsps  have  been
implicated in the pathogenesis of a number of
chronic  inflammatory  and  autoimmune  dis-
eases,  like  atherosclerosis,5 diabetes,6
rheumatoid arthritis,7 myasthenia gravis,8 and
inflammatory bowel disease (IBD).9 The latter
includes Crohn’s disease (CD) and ulcerative
colitis (UC), both affecting the gastrointesti-
nal tract and characterized by a chronic inflam-
mation with mucosal damage.10 The pathogen-
esis of CD and UC is not clear but stress is
among the suspected causative factors.11
In a previous work, we demonstrated that
Hsp60 and Hsp10 are increased in the affected
intestinal  mucosa  from  patients  with  CD  or
UC.12 Further, we demonstrated that mucosal
Hsp60  levels  in  UC  patients  decrease  after
therapy  with  either  mesalazine  alone  or
mesalazine plus probiotics, with the decrease
in the latter combined treatment being more
pronounced  than  in  patients  treated  with
mesalazine  alone.13 All  together  these  data
indicated that determination of Hsp60 in intes-
tinal mucosa could be a reliable biomarker to
monitor disease progression and response to
treatment. The data also supported the hypoth-
esis that Hsps, at least Hsp60, are active play-
ers in UC pathogenesis. In the present work,
we  measured  by  immunohistochemistry  the
mucosal  levels  of  other  Hsps  (i.e.,  Hsp10,
Hsp70,  and  Hsp90,  all  of  which  have  been
implicated  in  triggering/maintaining  inflam-




We included in this study mucosal biopsies
previously  obtained  from  40  patients  with
mildly  to  moderately  active  UC  without  sys-
temic comorbidities, as previously described.13
Disease activity was assessed using the Mayo
Score system from 0 to 12.14 Mildly to moder-
ately disease activity was defined by a score of
4 to 10. Biopsies were obtained at first diagno-
sis and after therapy. Patients were treated for
6 months with 1.2 or 2.4 g/die (depending on
disease  severity)  of  mesalazine  (5-ASA,
Asacol®,  Giuliani  &  Bracco,  Milan,  Italy)  or
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with both 5-ASA and 1 capsule/die of probiotics
(Acronelle®, Bromatech, Milan, Italy), as previ-
ously described.13 All the procedures followed
were in accordance with the ethical standards
of  the  responsible  committees  (institutional
and national) on human experimentation and
with  the  Helsinki  Declaration  of  1975  (as
revised  in  2008).  Informed  consents  were
obtained from all patients at the time of biopsy
and the study was approved by our local Ethics
Committee.
Tissue preparations
All biopsies were formalin-fixed and paraffin
embedded.  We  also  included  in  our  study  20
specimens  from  archival  tissue  of  formalin-
fixed,  paraffin-embedded  colon  mucosa  from
patients with non-specific colitis, as controls.
These patients underwent colonoscopy because
they were suspected to suffer from intestinal
inflammatory disease, but the histopathological
examination excluded presence of IDB. Five μm
sections were obtained from all paraffin blocks
and  were  de-waxed  and  re-hydrated  for
immunohistochemical analysis.
Immunohistochemistry
Immunostaining was done using an avidin-
biotin complex kit (LSAB2, DAKO, Carpinteria,
CA,  USA),  as  previously  described.15 Briefly,
after incubation for 10 min with serum-free
protein blocking, the following primary anti-
bodies were added to the sections: anti-Hsp10
(dilution 1:400, Cat. No. SPA-110, StressGen
Biotechnologies Co., Victoria, BC, Canada), or
anti-Hsp70  (dilution  1:200,  Cat.  No.  SC-24,
Santa  Cruz  Biotechnology,  Santa  Cruz,  CA,
USA), or anti-Hsp90 (dilution 1:200, Cat. No.
SC-13119,  Santa  Cruz  Biotechnology).
Appropriate positive controls, as well as non-
immune serum for negative controls, were run
concurrently.  3-3'-diaminobenzidine  (DAB
chromogen  solution,  DAKO,  Glostrup,
Denmark) was used as developer chromogen.
Nuclear  counterstaining  was  done  using
haematoxylin  (DAKO).  Two  independent
observers  (FR  and  FC)  examined  the  speci-
mens in a blind (code marked) procedure and
performed a quantitative analysis to determine
the percentage of cells positive for Hsps both
in epithelium (Ep) and lamina propria (LP) of
colon  mucosa.  Results  were  expressed  in  a
semiquantitative scale (-: 0%; +: 1-33%; ++:
34-66%; +++: 67-100%). All the observations
were made at a magnification of 400X and the
means of duplicate counts were used for statis-
tical analyses.
Statistical analyses
Data obtained from immunohistochemistry
evaluations were plotted using Microsoft Excel
software  (Microsoft  Italia,  Milan,  Italy).
Statistical analyses were carried out using the
GraphPad Prism 4.0 package (GraphPad Inc.,
San  Diego,  CA,  USA).  Standard  statistical
analyses were employed to calculate the means
and  the  standard  deviations  (SD).  One-way
analysis of variance was used to assess signif-
icant differences within the data. Differences
between the means were considered signifi-
cant when a value of P<0.05 was obtained. In
order to have an indication on the variability of
immunoreactivity data obtained by the differ-
ent observers, the coefficient of variation was
calculated using both the inter-observer and
intra-observers kappa statistics.
Finally, we performed a correlation analysis
between immunohistochemical levels of Hsps
and of inflammatory markers, i.e., CD3, CD4,
CD8,  CD20,  and  CD68  (data  that  we  have
obtained  in  a  previous  work13),  using  the
Pearson’s test. For correlation graphs, linear
regression was also calculated to reflect the
type of correlation between the chosen vari-
ables. Data were considered significant at an
alpha-level of 5%.
Results
We  divided  the  samples  in  four  groups:
mucosa obtained at time of diagnosis (group
T0); mucosa obtained after 6 months of treat-
ment  with  1.2  or  2.4  g/die  of  5-ASA  (group
T1a); mucosa obtained after 6 months of treat-
ment  with  5-ASA  +  probiotics  (group  T1b);
mucosa obtained from patients with non-spe-
cific  colitis,  as  control  (group  C).  Figure  1
shows representative pictures of immunohis-
tochemical  results  and  the  pertinent  semi-
quantitative data are displayed in Table 1, in
which the levels of the Hsps investigated are
shown for the epithelium (Ep) and lamina pro-
pria (LP). Hsps levels in T0 specimens tended
to be higher than in the controls (C) (P<0.05).
Hsp10 levels in Ep and LP were lower in the
T1a and in T1b groups (P<0.05), compared to
T0, with the most marked decrease occurring
in the T1b group (T0 vs T1b:P<0.001; T1a vs
T1b: P<0.005). The Hsp10 levels in the T1b
group were comparable to those of the con-
trols, C (P>0.05).
Hsp70 levels tended to be higher in Ep than
in LP, in which its positivity was mild. Ep levels
declined significantly from T0 through T1a to
T1b (T0 Œ T1a: P<0.05; T0 Œ T1b: P<0.005;
T1a Œ T1b: P<0.01). T1b levels were compara-
ble to those of controls, C (P>0.05).
Hsp90 levels were also higher in Ep than in
LP. However, its levels in Ep did not present any
significant change among Groups T0, T1a, and
T1b, while Group C had significant lower levels
(P<0.01). Hsp90 levels in LP of T0 and T1a did
not  change  significantly.  By  contrast,  they
were lower in T1b (T0 vs T1b: P<0.05; T1a vs
T1b: P<0.05) and in C (T0 vs C: P<0.05; T1a vs
C: P<0.05; T1b vs C: P<0.05). Figure 2 summa-
rizes graphically the main findings.
The inter-observer and intra-observer kappa
statistics for semiquantitative measurements
of  immunohistochemical  reactions  showed
values of 0.80 and 0.90, respectively.
The correlation analysis between immuno-
histochemical levels of Hsps and inflammatory
markers in lamina propria showed a linear cor-
relation only between Hsp90 and CD4 levels in
both  T0  (r=  +0.811;  P<0.005)  and  T1a  (r=
+0.732; P<0.005) groups (Figure 3).
Discussion
Ulcerative  colitis  (UC)  affects  the  large
bowel, particularly rectum and colon, in which
it presents characteristic ulcers.12 In the intes-
tinal mucosa, the lamina propria (LP) is infil-
trated by abundant inflammatory cells, while
the  epithelium  (Ep)  undergoes  cycles  of
destruction and repair by regeneration of basal
cells.16
Although it is not universally accepted, UC
is believed to have an autoimmune origin.17
Patients may develop systemic comorbidities
and  complications  beyond  the  colon.  These
include  aphthous  ulcers  of  the  mouth,18
uveitis,19 arthritis,20 erythema nodosum,21 pyo-
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Table 1. Semiquantitative evaluation of Hsp levels in the intestinal mucosa of patients
with ulcerative colitis and controls with non-specific colitis*.
Hsp Mucosal layer T0° T1a T1b C
Hsp10 Ep +++ ++ ++
LP +++ ++ ++
Hsp70 Ep +++ ++ ++
LP ++ + +
Hsp90 Ep +++ +++ +++ +
LP ++ ++ ++
*The immunohistochemical results are indicated in a semiquantitative scale (-: 0%; +: 1-33%; ++: 34-66%; +++: 67-100%); °T0, T1a,
T1b, and C, mucosa taken: at time of diagnosis, after 6 months of treatment with 5-ASA, after 6 months of treatment with 5-ASA +
probiotics, and from patients with non-pecific colitis (controls), respectively; Ep, epithelium; LP, lamina propria.[page 212] [European Journal of Histochemistry 2011; 55:e38]
derma  gangrenosum,21 hemolytic  anemia,22
and autoimmune hepatitis.23
Many  of  these  autoimmune  comorbidities
have already been shown to be accompanied by
increased levels of Hsps. For example, Hsp70
and  Hsp90  have  been  found  to  increase  in
autoimmune arthritis;24,25 Hsp70 was implicat-
ed in the development of autoimmune hepati-
tis;26 and levels of Hsp10, Hsp70, and Hsp90, as
well as Hsp60, have been found to change in
parallel with the development of large bowel
cancer,27-29the most severe complication of UC.
Hsp10  is  classically  considered  the  Hsp60
co-chaperonin, with both working inside mito-
chondria  for  assisting  the  correct  folding  of
proteins.30 However, Hsp10 can also be found
in extramitochondrial sites as well as in the
extracellular  environment,31 although  the
mechanism(s) responsible of its secretion has
not  yet  been  elucidated.  Extracellular  Hsp10
seems  to  have  immunomodulatory  activity,
favoring the implant of blastocyst,32 as well as
tumor progression.33
Hsp70 and Hsp90 are two of the most stud-
ied members of the Hsp family.34,35 They both
have chaperone functions inside cells forming
cytosolic chaperoning machines.34 In addition,
they occur also in extracellular sites triggering
immune  system  reactions,  thus  having  pro-
inflammatory effects.36,37
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Figure 1. Representative pictures of immunohistochemical results. This figure shows
microphotographs of immunostaining for Hsp10, Hsp70, and Hsp90 in all groups stud-
ied T0, T1a, T1b, and C, with mucosa sampled: at time of diagnosis, after 6 months of
treatment with 5-ASA, after 6 months of treatment with 5-ASA + probiotics, and from
patients with non-specific colitis (controls), respectively. Positivity appears brown. Scale
bars: 200 µm.
Figure  3.  Positive  correlation  between
Hsp90 and CD4 levels in Groups T0 (A)
and  T1a  (B).  Linear  regression  analysis
between the levels of Hsp10, Hsp70, and
Hsp90  with  the  levels  of  inflammatory
markers  (CD3,  CD4,  CD8,  CD20,  and
CD68) demonstrated a positive correlation
only  between  Hsp90  and  CD4  only  in
Groups T0 and T1a, as shown in the figure.
The  levels  of  the  inflammatory  markers
were determined in a previous work.13
Figure 2. Graphic summary of the main findings. Statistical analyses of immunohisto-
chemical data showed significant differences between T0 and T1a (*) and between T0/T1a
and T1b (^) in epithelium (Ep) for Hsp10 and Hsp70 and in lamina propria (LP) for
Hsp10 and Hsp90. Vertical axis: semiquantitative scale, as explained in the first footnote
for Table 1.[European Journal of Histochemistry 2011; 55:e38] [page 213]
In this work, we found that the three Hsps
we  studied  were  elevated  in  the  intestinal
mucosal of all patients at the time of diagnosis.
We also found that the Hsp levels changed sig-
nificantly  after  therapy.  For  example,  Hsp10
decreased in both the Ep and the LP in the T1a
and T1b groups; Hsp70 decreased in T1a and
T1b but only in the Ep; and Hsp90 decreased
only in T1b and only in the LP.
Very little information exists on Hsp10 in
UC and on the role this chaperonin might play
in diagnostics as biomarker and in disease as
a pathogenetic factor. In a previous work, we
demonstrated that Hsp10 levels are increased
in the intestinal mucosa of both CD and UC,
compared to normal mucosa, and that it often
co-localizes with Hsp60 in the same cells, both
in  Ep  and  LP.12 The  results  presented  here
show that Hsp10 levels in UC mucosa decrease
after therapy. This decline is similar to that we
previously described for Hsp60 after therapy.13
However, in contrast to Hsp60, Hsp10 has been
described  as  an  anti-inflammatory  agent.
Indeed, some clinical trials have already been
performed  demonstrating  the  usefulness  of
this protein in reducing inflammation in some
autoimmune processes, as multiple sclerosis,38
severe  plaque  psoriasis,39 and  rheumatoid
arthritis.40 Hence, we can postulate that the
Hsp10 increase in UC at the time of diagnosis
reflects an attempt of the mucosa to reduce the
inflammation  that  is  destroying  the  tissue;
after  therapy,  when  inflammation  declines,
Hsp10  levels  in  mucosal  cells  concomitantly
decrease.  By  contrast,  it  seems  that  Hsp70
does not participate in the inflammation of the
UC mucosa, since its levels in LP are common-
ly low and they did not present any change in
the Groups we studied. Hsp70 could be consid-
ered  a  protective  molecule  for  Ep  cells.  For
instance, mice mutants for Hsp70, treated with
a  combination  of  chemical  compounds  that
promote  colitis  and  colon  carcinogenesis,
developed histological and molecular features
of UC and cancer, while wild-type animals did
not become sick.41 All together, these results
are in agreement with previous studies that
postulated a protective role of Hsp70 in UC.42
However, in another study Hsp70 could not be
detected  immunohistochemically  in  mucosa
from UC patients.43
In an earlier work, Hsp90 was detected by
immunohistochemistry  in  Ep  and  LP  but  no
differences could be found in the intensity of
staining or localization in patients with IBD
compared  to  controls.44 By  contrast,  in  our
work reported here Hsp90 levels were higher
in UC mucosa than in the mucosa of non-spe-
cific colitis and this could explain the discrep-
ancy between our studies and those that used
normal mucosa as base-line control. In addi-
tion, we did not detect any changes in Hsp90
Ep levels after therapy. By contrast, treatment
with 5-ASA + probiotics reduced Hsp90 levels
in LP, while treatment with 5-ASA alone did not
have any effect. In this regard, we found a lin-
ear correlation between Hsp90 and CD4 levels
in LP of both T0 and T1a groups.
Hsp90 from the LP could reach the blood-
stream and thus interact with the immune sys-
tem since it has been reported that the chaper-
one is involved in activation of cells pertaining
to  innate  and  adaptive  immunities,  thereby
affecting inflammation and autoimmunity.26,45
Based on results obtained with an experimen-
tal model using rodents, it has been proposed
that a synthetic Hsp90 inhibitor, able to block
LPS-induced  TLR4  signaling  of  CD4+ cells,
could  be  applicable  to  treatment  of  autoim-
mune  diseases  involving  inflammation  and
activation of the adaptive immune response.26
The data were in agreement with a previous
work  in  which  another  Hsp90  inhibitor  was
found to reduce inflammation, cartilage dam-
age,  and  bone  resorption  in  a  model  of
rheumatoid  arthritis.45 Thus,  we  cannot
exclude that increased levels of Hsp90 in LP of
patients  with  UC  could  be  followed  by  an
inflammatory reaction triggered via CD4+ cells
or by invasion of blood by the chaperone lead-
ing to autoimmune phenomena in extra-intes-
tinal sites. We did not have blood samples from
the patients investigated in the study reported
here  and,  therefore,  we  could  not  measure
Hsp90  in  the  sera  of  these  patients,  which
would have allowed us to correlate chaperone
levels in mucosa and in sera with the occur-
rence of comorbidities. If a positive correlation
is found, one can then think that treatment of
UC with 5-ASA plus probiotics should include
attempts to reduce Hsp90 levels. The results of
our  correlation  analysis  between  Hsp90  and
CD4 levels in LP support this view.
In conclusion, Hsp10, Hsp70, and Hsp90 lev-
els  were  increased  in  the  mucosa  of  UC
patients at the time of diagnosis, compared to
non-specific  colitis.  These  levels  decreased
after therapy. Combined treatment with 5-ASA
and probiotics produced the greatest reduction
in the Hsp levels, namely, the same pattern we
had already found for Hsp60.13 This result is
largely  in  agreement  with  other  studies
assessing the value of probiotics in treatment
of IBD like UC.46,47All together, our results indi-
cate that determination of Hsp levels in intes-
tinal mucosa as done in this study has a prom-
ising  potential  for  monitoring  response  to
treatment in UC, and open new avenues for
investigating the pathogenetic mechanisms of
this disease, particularly in what concerns the
role of the chaperones in the initiation and
progression of the intestinal lesions.
References
1. Macario AJL, Lange M, Ahring BK, Conway
de Macario E. Stress genes and proteins in
the  archaea.  Microbiol  Mol  Biol  Rev
1999;63:923-67.
2. Kampinga HH. Chaperones in preventing
protein  denaturation  in  living  cells  and
protecting  against  cellular  stress.  Handb
Exp Pharmacol 2006;172:1-42.
3. Prohászka  Z,  Füst  G.  Immunological
aspects  of  heat-shock  proteins-the  opti-
mum stress of life. Mol Immunol 2004;41:
29-44. 
4. Cappello F, Conway de Macario E, Di Felice
V, Zummo G, Macario AJL. Chlamydia tra-
chomatis infection and anti-Hsp60 immu-
nity: the two sides of the coin. PLoS Pathog
2009;5:e1000552. 
5. Wick G, Knoflach M, Kind M, Henderson B,
Bernhard  D.  Heat  shock  proteins  and
stress in atherosclerosis. Autoimmun Rev
2004;3:S30-1. 
6. Lai Y, Chen C, Linn T. Innate immunity and
heat shock response in islet transplanta-
tion. Clin Exp Immunol 2009;157:1-8. 
7. Huang  MN,  Yu  H,  Moudgil  KD.  The
involvement of heat-shock proteins in the
pathogenesis of autoimmune arthritis: a
critical appraisal. Semin Arthritis Rheum
2010;40:164-75. 
8. Cappello F, Marino Gammazza A, Zummo
L,  Conway  de  Macario  E,  Macario  AJL.
Hsp60 and AChR cross-reactivity in myas-
thenia  gravis:  An  update.  J  Neurol  Sci
2010;292:117-8.
9. Otaka M, Odashima M, Watanabe S. Role
of heat shock proteins (molecular chaper-
ones)  in  intestinal  mucosal  protection.
Biochem  Biophys  Res  Commun  2006;
348:1-5.
10.  Szigethy  E,  McLafferty  L,  Goyal  A.
Inflammatory bowel disease. Child Adolesc
Psychiatr Clin N Am 2010;19:301-18.
11. Kaser A, Blumberg RS. Autophagy, micro-
bial  sensing,  endoplasmic  reticulum
stress, and epithelial function in inflam-
matory  bowel  disease.  Gastroenterology
2011;140:1738-47.
12. Rodolico  V,  Tomasello  G,  Zerilli  M,
Martorana A, Pitruzzella A, Marino Gam  -
mazza A, et al. Hsp60 and Hsp10 increase
in colon mucosa of Crohn’s disease and
ulcerative colitis. Cell Stress Chaperones
2010;15:877-84.
13. Tomasello  G,  Rodolico  V,  Zerilli  M,
Martorana A, Bucchieri F, Pitruzzella A, et
al. Changes in immunohistochemical lev-
els and subcellular localization after thera-
py and correlation and colocalization with
Brief Report[page 214] [European Journal of Histochemistry 2011; 55:e38]
CD68 suggest a pathogenetic role of Hsp60
in  ulcerative  colitis.  Appl  Immunohi  -
stochem Mol Morphol 2011; [Epub ahead
of print].
14. Heuschen  UA,  Allemeyer  EH,  Hinz  U,
Autschbach F, Uehlein T, Herfarth C, et al.
Diagnosing pouchitis: comparative valida-
tion of two scoring systems in routine fol-
low-up. Dis Colon Rectum 2002;45:776-86.
15. Cappello F, Barnes L. Synovial sarcoma and
malignant  mesothelioma  of  the  pleura:
review, differential diagnosis and possible
role of apoptosis. Pathology 2001;33:142-8. 
16. Gramlich  T,  Petras  RE.  Pathology  of
inflammatory  bowel  disease.  Semin
Pediatr Surg 2007;16:154-63. 
17. Flanagan  P,  Campbell  BJ,  Rhodes  JM.
Bacteria in the pathogenesis of inflamma-
tory  bowel  disease.  Biochem  Soc  Trans
2011;39:1067-72. 
18. Miyamoto  NT  Jr,  Borra  RC,  Abreu  M,
Weckx LL, Franco M. Immune-expression
of HSP27 and IL-10 in recurrent aphthous
ulceration. J Oral Pathol Med 2008;37:462-
7. 
19. Freeman  HJ.  Pouchitis-associated  iritis
(uveitis)  following  total  proctocolectomy
and  ileal  pouch-to-anal  anastomosis  in
ulcerative  colitis.  Can  J  Gastroenterol
2001;15:131-3. 
20. Yanai H, Hanauer SB. Assessing response
and loss of response to biological therapies
in IBD. Am J Gastroenterol 2011;106:685-
98. 
21. Polcz  M,  Gu  J,  Florin  T.  Pyoderma  gan-
grenosum in inflammatory bowel disease:
the experience at Mater Health Services'
Adult Hospital 1998-2009. J Crohns Colitis
2011;5:148-51. 
22. Leo  Carnerero  E,  Aoufi  S,  Montero
Cuadrado  I,  Herrera  Martin  P,  Herrera
Justiniano  JM.  Autoimmune  hemolytic
anemia associated with ulcerative colitis:
response to infliximab. Am J Gastroenterol
2009;104:2370-1. 
23. Saich R, Chapman R. Primary sclerosing
cholangitis,  autoimmune  hepatitis  and
overlap syndromes in inflammatory bowel
disease.  World  J  Gastroenterol  2008;14:
331-7. 
24. Wieten  L,  van  der  Zee  R,  Spiering  R,
Wagenaar-Hilbers J, van Kooten P, Broere
F, et al. A novel heat-shock protein coin-
ducer boosts stress protein Hsp70 to acti-
vate T cell regulation of inflammation in
autoimmune  arthritis.  Arthritis  Rheum
2010;62:1026-35. 
25. Conroy  SE,  Faulds  GB,  Williams  W,
Latchman DS, Isenberg DA. Detection of
autoantibodies to the 90 kDa heat shock
protein in systemic lupus erythematosus
and  other  autoimmune  diseases.  Br  J
Rheumatol 1994;33:923-6. 
26. Yun TJ, Harning EK, Giza K, Rabah D, Li P,
Arndt  JW,  et  al.  EC144,  a  synthetic
inhibitor of heat shock protein 90, blocks
innate and adaptive immune responses in
models of inflammation and autoimmuni-
ty. J Immunol 2011;186:563-75. 
27. Cappello F, Bellafiore M, Palma A, David S,
Marcianò  V,  Bartolotta  T,  et  al.  60KDa
chaperonin  (HSP60)  is  over-expressed
during  colorectal  carcinogenesis.  Eur  J
Histochem 2003;47:105-10. 
28. Cappello  F,  David  S,  Peri  G,  Farina  F,
Conway de Macario E, Macario AJL, et al.
Hsp60: molecular anatomy and role in col-
orectal  cancer  diagnosis  and  treatment.
Front Biosci 2011;3:341-51.
29. Cappello F, Czarnecka AM, La Rocca G, Di
Stefano A, Zummo G, Macario AJL. Hsp60
and Hspl0 as antitumor molecular agents.
Cancer Biol Ther 2007;6:487-9.
30. Czarnecka AM, Campanella C, Zummo G,
Cappello F. Heat shock protein 10 and sig-
nal transduction: a "capsula eburnea" of
carcinogenesis?  Cell  Stress  Chaperones
2006;11:287-94. 
31. Corrao  S,  Campanella  C,  Anzalone  R,
Farina F, Zummo G, Conway de Macario E,
et al. Human Hsp10 and Early Pregnancy
Factor  (EPF)  and  their  relationship  and
involvement in cancer and immunity: cur-
rent knowledge and perspectives. Life Sci
2010;86:145-52. 
32. Athanasas-Platsis  S,  Corcoran  CM,  Kaye
PL, Cavanagh AC, Morton H. Early preg-
nancy factor is required at two important
stages  of  embryonic  development  in  the
mouse.  Am  J  Reprod  Immunol  2000;43:
223-33. 
33. Akyol  S,  Gercel-Taylor  C,  Reynolds  LC,
Taylor  DD.  HSP-10  in  ovarian  cancer:
expression and suppression of T-cell sig-
naling. Gynecol Oncol 2006;101:481-6. 
34. Macario AJL, Conway de Macario E. Sick
chaperones, cellular stress, and disease. N
Engl J Med 2005;353:1489-501. 
35. Macario  AJL,  Brocchieri  L,  Shenoy  AR,
Conway de Macario E. Evolution of a pro-
tein-folding machine: genomic and evolu-
tionary analyses reveal three lineages of
the archaeal hsp70(dnaK) gene. J Mol Evol
2006;63:74-86.
36. Vega  VL,  Rodríguez-Silva  M,  Frey  T,
Gehrmann M, Diaz JC, Steinem C, et al.
Hsp70 translocates into the plasma mem-
brane after stress and is released into the
extracellular environment in a membrane-
associated  form  that  activates
macrophages.  J  Immunol  2008;180:4299-
307.
37. Oura J, Tamura Y, Kamiguchi K, Kutomi G,
Sahara  H,  Torigoe  T,  et  al.  Extracellular
heat  shock  protein  90  plays  a  role  in
translocating  chaperoned  antigen  from
endosome  to  proteasome  for  generating
antigenic peptide to be cross-presented by
dendritic cells. Int Immunol 2011;23:223-
37.
38. Broadley  SA,  Vanags  D,  Williams  B,
Johnson  B,  Feeney  D,  Griffiths  L,  et  al.
Results of a phase IIa clinical trial of an
anti-inflammatory  molecule,  chaperonin
10,  in  multiple  sclerosis.  Mult  Scler
2009;15:329-36.
39. Williams B, Vanags D, Hall S, McCormack
C, Foley P, Weiss J, et al. Efficacy and safe-
ty of chaperonin 10 in patients with mod-
erate to severe plaque psoriasis: evidence
of utility beyond a single indication. Arch
Dermatol 2008;144:683-5.
40. Vanags D, Williams B, Johnson B, Hall S,
Nash P, Taylor A, et al. Therapeutic effica-
cy and safety of chaperonin 10 in patients
with rheumatoid arthritis: a double-blind
randomised trial. Lancet 2006;368:855-63.
41. Tao Y, Hart J, Lichtenstein L, Joseph LJ,
Ciancio  MJ,  Hu  S,  et  al.  Inducible  heat
shock protein 70 prevents multifocal flat
dysplastic lesions and invasive tumors in
an  inflammatory  model  of  colon  cancer.
Carcinogenesis 2009;30:175-82.
42. Nam SY, Kim N, Kim JS, Lim SH, Jung HC,
Song  IS.  Heat  shock  protein  gene  70-2
polymorphism is differentially associated
with the clinical phenotypes of ulcerative
colitis  and  Crohn's  disease.  J
Gastroenterol Hepatol 2007;22:1032-8.
43. Lu XP, Omar RA, Chang WW. Immunocy  -
tochemical expression of the 70 kD heat
shock protein in ischaemic bowel disease.
J Pathol 1996;179:409-13.
44. Stahl M, Ludwig D, Fellermann K, Stange
EF.  Intestinal  expression  of  human  heat
shock protein 90 in patients with Crohn's
disease and ulcerative colitis. Dig Dis Sci
1998;43:1079-87.
45. Rice JW, Veal JM, Fadden RP, Barabasz AF,
Partridge JM, Barta TE, et al. Small mole-
cule  inhibitors  of  Hsp90  potently  affect
inflammatory disease pathways and exhib-
it activity in models of rheumatoid arthri-
tis. Arthritis Rheum 2008;58:3765-75.
46. Do VT, Baird BG, Kockler DR. Probiotics for
maintaining remission of ulcerative colitis
in adults. Ann Pharmacother 2010;44:565-
71.
47. Haller D, Antoine JM, Bengmark S, Enck P,
Rijkers  GT,  Lenoir-Wijnkoop  I.  Guidance
for substantiating the evidence for benefi-
cial  effects  of  probiotics:  probiotics  in
chronic  inflammatory  bowel  disease  and
the functional disorder irritable bowel syn-
drome. J Nutr 2010;140:690S-7.
Brief Report